FDA Proposes Fee Cuts to Keep Early Trials in the U.S., Adds Penalties for Overseas Development Summary: In early PDUFA VI reauthorization talks, the FDA proposed lowering user fees for companies running phase 1 trials in the U.S. while imposing higher or additional annual fees on developers conducting early-stage work abroad, aiming to incentivize domestic […]